In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lexicon Pharmaceuticals Inc.

www.lexpharma.com

Latest From Lexicon Pharmaceuticals Inc.

EU 2019 Approvals: Novel Therapies Make Strong Showing

Bluebird bio’s gene therapy Zynteglo, Akcea’s antisense drug Waylivra and BioMarin’s enzyme substitution therapy Palynziq were among the novel innovative medicines that were approved in Europe in 2019. 

Europe Approvals

As Sanofi Exits Diabetes R&D, Meaning Of ‘Diabetes R&D’ Blurs

Cardiovascular outcome trials are driving development in blockbuster SGLT-2 inhibitor and GLP-1 agonist classes to look beyond HbA1c levels to focus on cardiovascular and renal protective effects.

Metabolic Disorders Research & Development

Deal Watch: Castle Creek Likes Partner Fibrocell Enough To Buy It

Dermatology-focused regenerative medicine firm Fibrocell has been reviewing strategic opportunities for more than a year; April’s FCX-007 license deal with Castle Creek results in buyout.

Deals Business Strategies

With $260m Settlement From Sanofi, Lexicon Looks For New Zynquista Partner

Sanofi terminated its alliance for the SGLT1/2 inhibitor Zynquista, giving Lexicon full control of development in type 1 and type 2 diabetes, but it is seeking a new partner ideally with a European footprint.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Lexicon Genetics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Lexicon Pharmaceuticals Inc.
  • Senior Management
  • Lonnel Coats, Pres. & CEO
    Jeffrey L Wade, EVP, CFO
    Praveen Tyle, PhD, EVP, R&D
    Pablo Lapuerta, MD, EVP, CMO
  • Contact Info
  • Lexicon Pharmaceuticals Inc.
    Phone: (281) 863-3000
    8800 Technology Forest Pl.
    The Woodlands, TX 77381-1160
    USA
UsernamePublicRestriction

Register